Asuragen Partners with Wave Life Sciences to Develop Companion Diagnostics for Huntington’s Disease

Asuragen Partners with Wave Life Sciences to Develop Companion Diagnostics for Huntington’s Disease

Publication date: Nov 26, 2019

Asuragen, Inc. , a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, and Wave Life Sciences, a clinical-stage genetic medicines company developing life-changing treatments for people battling devastating diseases, have entered into an agreement for the development and commercialization of companion diagnostics for Wave’s investigational allele-selective therapeutic programs targeting Huntington’s disease (HD).

The companion diagnostics that Asuragen will develop build on the experience gained by Wave using a single-nucleotide polymorphism (SNP) phasing methodology in Wave’s current clinical trials in HD and a previous observational study.

-Our partnership with Asuragen for companion diagnostic development was a natural fit in light of their deep knowledge and expertise with challenging molecular targets, diagnostic regulatory experience and their growing presence in the neurogenetics testing market,” said Jaya Goyal, Ph. D., Vice President of Bioanalytics, Pharmacology, and Biomarker Development at Wave Life Sciences.

Asuragen will leverage this technology to develop companion diagnostic tests that size and phase HTT CAG repeats with two different SNPs targeted by Wave’s WVE-120101 and WVE-120102 investigational therapeutic programs.

Developing a companion diagnostic for Wave’s novel allele-selective silencing program in HD is a great example of how our products will continue to advance personalized medicine,” said Matthew McManus, M. D., Ph. D. president and CEO of Asuragen.

Concepts Keywords
Aging SNP
Allele Diagnostic tests
Biomarker Single nucleotide polymorphism
Brain Medical genetics
CEO Personalized medicine
Clinical Trials Companion diagnostic
Foundry Molecular diagnostics
Genetic Population genetics
Huntington DNA
MRNA Molecular biology
Mutant Medical tests
Nerve Biotechnology
Neurological Disorders Medicine
Observational Study Branches of biology
Oligonucleotides Disorder
Oncology Diseases
Optimization Diagnostic systems
Personalized Medicine
Proprietary Software
Single Nucleotide Polymorphism
Vice President
Wild Type


Type Source Name
drug DRUGBANK Coenzyme M
disease MESH aging
disease MESH diagnosis
disease MESH cancer
disease MESH neurological disorders
disease MESH multiple
disease MESH development

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *